Targeting the NF-E2-related Factor 2 Pathway: a Novel Strategy for Glioblastoma (review)
Affiliations
Glioblastoma is the most common and malignant subtype among all brain tumors. Nuclear factor erythroid 2-related factor 2 (Nrf2) is an essential component of cellular defense against a variety of endogenous and exogenous stresses. A marked increase in research over the past few decades focusing on Nrf2 and its role in regulating glioblastoma has revealed the potential value of Nrf2 in the treatment of glioblastoma. In the present review, we discuss a novel framework of Nrf2 in the regulation of glioblastoma and the mechanisms regarding the downregulation of Nrf2 in treating glioblastoma. The candidate mechanisms include direct and indirect means. Direct mechanisms target tumor molecular pathways in order to overcome resistance to chemotherapy and radiotherapy, to inhibit proliferation, to block invasion and migration, to induce apoptosis, to promote differentiation, to enhance autophagy and to target glioblastoma stem cells. Indirect mechanisms target the reaction between glioblastoma cells and the surrounding microenvironment. Overall, the value of the Nrf2 pathway in glioblastoma provides a promising opportunity for new approaches by which to treat glioblastoma.
Ying M, Yang Y, Huo Q, Sun J, Hong X, Yang F Sci Rep. 2024; 14(1):24057.
PMID: 39402078 PMC: 11473639. DOI: 10.1038/s41598-024-74599-8.
Borax induces ferroptosis of glioblastoma by targeting HSPA5/NRF2/GPx4/GSH pathways.
Tuncer C, Hacioglu C J Cell Mol Med. 2024; 28(7):e18206.
PMID: 38494858 PMC: 10945083. DOI: 10.1111/jcmm.18206.
Impact of Nrf2 overexpression on cholangiocarcinoma treatment and clinical prognosis.
Lee H, Min S, Cho M, Lee H Korean J Clin Oncol. 2023; 19(1):18-26.
PMID: 37449395 PMC: 10352705. DOI: 10.14216/kjco.23004.
Alhaddad L, Osipov A, Leonov S Int J Mol Sci. 2022; 23(21).
PMID: 36362359 PMC: 9656305. DOI: 10.3390/ijms232113577.
Exploring the role of Nrf2 signaling in glioblastoma multiforme.
Awuah W, Toufik A, Yarlagadda R, Mikhailova T, Mehta A, Huang H Discov Oncol. 2022; 13(1):94.
PMID: 36169772 PMC: 9519816. DOI: 10.1007/s12672-022-00556-4.